The year in cardiology: heart failure
█ Current opinion
Authors:
John G. F. Cleland1, 2, 3, Alexander R. Lyon2, 4,Theresa McDonagh5, 6, and John J. V. McMurray3
1Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow G12 8QQ, UK;
2National Heart & Lung Institute, Imperial College, London, UK;
3British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8QQ, UK;
4Royal Brompton Hospital, London, UK;
5King’s College Hospital, London, UK; and
6King’s College London, London, UK
Preamble
The past year has brought many new concepts and an abundance of new data on the nature, management, and outcome of heart failure. The pace of change is accelerating. We look forward to an exciting new decade of research. The prognosis of cardiovascular disease is determined to a large extent by the ability to delay or prevent the development and progression of heart failure (1). Accordingly, attention is shifting to earlier diagnosis of and intervention for heart failure. Patients with type-2 diabetes mellitus (T2DM) (2) or coronary artery disease (CAD) (3) have a relatively good prognosis unless plasma concentrations of natriuretic peptides are increased, indicating important cardiac or renal dysfunction. Adoption of a simple ‘Universal Definition’ of heart failure based on natriuretic peptides would facilitate early diagnosis and treatment but lead to an enormous increase in its prevalence and demand upon medical services (4). We need to prepare for the impending shock.
ISSUE: CARDIOLOGIA HUNGARICA | 2020 | VOLUME 50, ISSUE 2
click here to read the full article |
click here to read the pdf |